Project
Novartis CAIN457R12301
Ongoing - recruitment active ยท 2022 until 2025
Rubbert-Roth Andrea, Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana
Type
Range
Units
Status
Start Date
End Date
Financing
Brief description/objective
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)